Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMB305 in Synovial Sarcoma
NCT03520959Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Vaccine mRNA, mRNA Vaccines, Split/Subunit Vaccines
- Countries
- 2
01
Overview
A Phase 3 trial of CMB305 in synovial sarcoma (SS), sponsored by Merck & Co.. Started Sep 2018; status: terminated.
02
Drugs
CMB305
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT03520959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520959.